AI reading of ECGs to find occlusion myocardial infarction
Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
This trial tests whether an AI tool that reads ECGs can help doctors identify and treat occlusion myocardial infarction faster in adults with suspected acute coronary syndrome who don't meet STEMI criteria.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cardiocentro Ticino Academic / other |
| Locations | 1 site (Lugano, Canton Ticino) |
| Trial ID | NCT07077057 on ClinicalTrials.gov |
What this trial studies
Adults presenting with symptoms of acute coronary syndrome but without clear ST-elevation are randomized 1:1 to have their ECG interpreted with an AI tool (PMcardio) or to standard care. The study compares time to coronary intervention and infarct size, with infarct size measured by peak high-sensitivity troponin T (hsTnT). Key eligibility includes age 18+, symptom onset within 24 hours, and ability to give informed consent, while patients with a clear STEMI diagnosis, pregnancy/lactation, or legal incapacity are excluded. The trial is conducted at Cardiocentro Ticino in Lugano and focuses on care timelines and biomarker outcomes between the two arms.
Who should consider this trial
Good fit: Adults (18+) who present with symptoms of acute coronary syndrome within 24 hours, do not meet clinical STEMI criteria, and can provide informed consent are ideal candidates.
Not a fit: Patients with a clear STEMI diagnosis, those presenting more than 24 hours after symptom onset, pregnant or lactating individuals, and those unable to consent are unlikely to receive benefit from this trial.
Why it matters
Potential benefit: If successful, the AI tool could speed diagnosis and treatment of occlusion MIs, potentially reducing heart muscle damage and improving recovery.
How similar studies have performed: Prior studies of AI ECG algorithms have shown promise in detecting acute ischemia and hidden myocardial infarction, but randomized evidence specifically for occlusion MI detection remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder/arm/jaw/back, fatigue, or light-headedness 2. Age: Patients aged 18 years or older. 3. Informed Consent: Patients able to provide informed consent Exclusion Criteria: 1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians. 2. Pregnancy or Lactation. 3. Legally incompetent to provide informed consent. 4. Symptoms onset\>24 hrs prior to clinical presentation.
Where this trial is running
Lugano, Canton Ticino
- Cardiocentro Ticino Institute — Lugano, Canton Ticino, Switzerland (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.